Hansoh Pharmaceutical Group Co. Ltd. has announced that their self-developed B7-H4-targeted antibody-drug conjugate, HS-20089, has been granted Breakthrough-Therapy-Designated Drug status by the National Medical Products Administration (NMPA) of China. This designation is for the proposed treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients. HS-20089, which utilizes a topoisomerase inhibitor payload, is currently undergoing multiple clinical trials in China, with the highest research stage being Phase III. The approval marks a significant step forward in the development of this promising therapy for gynecological tumors.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。